Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
OM
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q1.23
N/A
-10.79
vs -10.04
Q2.23
N/A
-10.34
vs -11.54
Q3.23
N/A
-10.64
vs -10.49
Q4.23
N/A
-8.85
vs -10.64
Q1.24
N/A
-8.55
vs -10.79
Q2.24
N/A
-7.05
vs -10.34
Q3.24
N/A
-5.85
vs -10.64
Q4.24
N/A
-5.55
vs -8.85
Q1.25
N/A
-0.94
vs -8.55
Q2.25
N/A
-0.86
vs -7.05
Sales Growth
YoY
Current
Estimates
Q1.23
+10%
33.5M vs 30.6M
Q2.23
+44%
36M vs 25.1M
Q3.23
+9%
30.4M vs 27.8M
Q4.23
-5%
30.5M vs 32M
Q1.24
-16%
28.2M vs 33.5M
Q2.24
-24%
27.4M vs 36M
Q3.24
-6%
28.7M vs 30.4M
Q4.24
-3%
29.5M vs 30.5M
Q1.25
-1%
27.8M vs 28.2M
Q2.25
+6%
29.1M vs 27.4M
Return on Equity
QoQ
Q1.23
-20%
-0.20
vs -0.17
Q2.23
-24%
-0.24
vs -0.20
Q3.23
-30%
-0.30
vs -0.24
Q4.23
-31%
-0.31
vs -0.30
Q1.24
-43%
-0.43
vs -0.31
Q2.24
-50%
-0.50
vs -0.43
Q3.24
-58%
-0.58
vs -0.50
Q4.24
-96%
-0.96
vs -0.58
Institutionnal Ownership
QoQ
Q1.23
163
163
vs 153
7%
Q2.23
155
155
vs 163
-5%
Q3.23
156
156
vs 155
1%
Q4.23
140
140
vs 156
-10%
Q1.24
114
114
vs 140
-19%
Q2.24
122
122
vs 114
7%
Q3.24
82
82
vs 122
-33%
Q4.24
78
78
vs 82
-5%
globenewswire.com
8 hours ago
fool.com
8 hours ago
zacks.com
11 hours ago
globenewswire.com
16 hours ago
Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
0.57 ( 5.34%)
Relative Strenght
99
Volume Buzz
63%
Earning Acce
Yes
Dist 52w H.
86%Forecast
308%2025-Revenue
-577%2025-EPS
-535%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
15.00(33.33%)
Number of analyst
1
Last analyst upgrade/downgrade
RBC Capital
downgradePrevious: Outperform
2024-08-08
Now: Sector Perform
RBC Capital
upgradePrevious: Sector Perform
2024-06-21
Now: Outperform
BTIG
initialisePrevious: Not converted
2024-04-08
Now: Buy
UBS
initialisePrevious: Not converted
2023-08-17
Now: Neutral
Relative Strength
OM
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|